# A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

> **NCT05744401** · PHASE2 · TERMINATED · sponsor: **Alector Inc.** · enrollment: 197 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** AL002

## Key facts

- **NCT ID:** NCT05744401
- **Lead sponsor:** Alector Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-04
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-02-05
- **Target enrollment:** 197 (ACTUAL)
- **Why stopped:** Parent study failed to meet the primary endpoint and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints.
- **Last updated:** 2026-02-25

## Collaborators

- AbbVie

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05744401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05744401, "A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05744401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*